Covaxin Production
- All
- News
- Videos
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Covaxin Production Slowed Down, This Is What Bharat Biotech Will Focus On
Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.
-
Health Minister Discusses Covaxin's Emergency Use Listing With WHO Chief
COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating timely, equitable and affordable access of COVID-19 health products by boosting their supply.
-
Monthly Production Of Covishield, Covaxin Planned To Be Increased: Centre
The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.
-
Health Minister Meets Top Vaccine Bosses, Takes Stock Of Production Status
Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.
-
Covishield, Covaxin Monthly Production To Be 120, 58 Million Doses Respectively: Centre
Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.
-
"Quality Issues Behind Covaxin Shortage": Government Vaccine Panel Chief
The supply of Bharat Biotech's Covaxin has been slowed down because the first few batches at the company's newest facility in Bengaluru were not of the right quality, a top government adviser has said.
-
Nearly 25 Crore Vaccine Doses Likely By August: Central Covid Panel
With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily aga
-
Production, Supply Of Covaxin Time-Taking Process: Bharat Biotech
Amid rising demand for COVID vaccines, Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.
-
Covaxin Has Reached "30 Cities In 30 Days": Bharat Biotech Amid Shortages
New shipments of Bharat Biotech's Covaxin have reached 30 cities in 30 days, the vaccine maker said this morning in a tweet as a shortage of doses continues to be a challenge in India's fight against coronavirus.
-
Centre Explores Possibility Of Covaxin Production Outside India: Report
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
-
Covaxin Production To Be Scaled Up By Additional 200 Million Doses
Bharat Biotech on Thursday said it's planning to ramp up the manufacturing capacity of its COVID-19 vaccine, Covaxin, by an additional 200 million doses per year.
-
Vaccine Makers Invited To Produce Covaxin To Address Shortage
The central government and Bharat Biotech are willing to invite other companies which want to produce Covaxin to help scale up its production, a top government advisor said on Thursday, as India grapples with a dire shortage of vaccines.
-
Believe Rs 3,000 Crore Will Reach Us, Not Waited, Borrowed: Adar Poonawalla
After the centre announced Rs 4,500 crore to boost production of the Covishield and Covaxin vaccines, Serum Institute of India says it has borrowed from banks to begin ramp-up of its vaccine immediately instead of waiting for the government's aid to
-
Bharat Biotech Scales Up Covaxin Production To 700 Million Doses Annually
To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, Covaxin, to 700 million doses per annum, the vaccine maker said on Tuesday.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Covaxin Production Slowed Down, This Is What Bharat Biotech Will Focus On
Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.
-
Health Minister Discusses Covaxin's Emergency Use Listing With WHO Chief
COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating timely, equitable and affordable access of COVID-19 health products by boosting their supply.
-
Monthly Production Of Covishield, Covaxin Planned To Be Increased: Centre
The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.
-
Health Minister Meets Top Vaccine Bosses, Takes Stock Of Production Status
Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.
-
Covishield, Covaxin Monthly Production To Be 120, 58 Million Doses Respectively: Centre
Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.
-
"Quality Issues Behind Covaxin Shortage": Government Vaccine Panel Chief
The supply of Bharat Biotech's Covaxin has been slowed down because the first few batches at the company's newest facility in Bengaluru were not of the right quality, a top government adviser has said.
-
Nearly 25 Crore Vaccine Doses Likely By August: Central Covid Panel
With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily aga
-
Production, Supply Of Covaxin Time-Taking Process: Bharat Biotech
Amid rising demand for COVID vaccines, Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.
-
Covaxin Has Reached "30 Cities In 30 Days": Bharat Biotech Amid Shortages
New shipments of Bharat Biotech's Covaxin have reached 30 cities in 30 days, the vaccine maker said this morning in a tweet as a shortage of doses continues to be a challenge in India's fight against coronavirus.
-
Centre Explores Possibility Of Covaxin Production Outside India: Report
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
-
Covaxin Production To Be Scaled Up By Additional 200 Million Doses
Bharat Biotech on Thursday said it's planning to ramp up the manufacturing capacity of its COVID-19 vaccine, Covaxin, by an additional 200 million doses per year.
-
Vaccine Makers Invited To Produce Covaxin To Address Shortage
The central government and Bharat Biotech are willing to invite other companies which want to produce Covaxin to help scale up its production, a top government advisor said on Thursday, as India grapples with a dire shortage of vaccines.
-
Believe Rs 3,000 Crore Will Reach Us, Not Waited, Borrowed: Adar Poonawalla
After the centre announced Rs 4,500 crore to boost production of the Covishield and Covaxin vaccines, Serum Institute of India says it has borrowed from banks to begin ramp-up of its vaccine immediately instead of waiting for the government's aid to
-
Bharat Biotech Scales Up Covaxin Production To 700 Million Doses Annually
To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, Covaxin, to 700 million doses per annum, the vaccine maker said on Tuesday.
